UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program

项目总结 加州大学戴维斯分校保罗·卡拉布雷西K12临床肿瘤学研究职业发展的总体目标 该计划(CDP)旨在培养临床医生或基础/翻译初级教员，使其成为独立的、耐心的- 在翻译、团队驱动的研究方面受过高度培训的面向癌症的研究人员。使用1)核心 能力，2)高级肿瘤学课程，3)职业发展，4)指导性研究，5)交叉 CDP每年提供两名新学者(任何时候六名)为期三年的职业生涯 发展计划旨在磨练远远超出其最初学科界限的想法和技能。 学者们将克服通常存在于临床和临床之间的语言和文化障碍 基础/翻译研究人员，利用加州大学戴维斯分校的协作研究环境， 参与多学科和翻译论坛，收集研究设计、临床方面的基本技能 试验开发、团队科学、拨款撰写、研究道德行为、沟通和职业生涯 发展。其愿景是通过培训内科科学家结合和 利用基础/相关科学进行临床试验(“临床跟踪”)，反之，推动基础研究 科学家致力于以患者为导向的药物开发和临床研究(“基础/翻译轨道”)。至 CDP学者在两位学者的指导下，保持对患者驱动的临床研究的重视 临床导师和基础/翻译导师将被要求开发和启动/实施他们自己的 培训期间由研究人员发起的临床试验。该计划将利用杰出的研究成果， NCI指定的加州大学戴维斯综合癌症中心的培训、评估专业知识和基础设施 中心、NCATS资助的临床和转化研究中心(CTSC)和医学院职业 发展计划。它将由一个组织严密的内部监督委员会进行监督和加强 和外部咨询委员会。总体而言，CDP寻求实现以下具体目标：1)提供 基于能力的教学课程，以促进团队科学，鼓励翻译研究，并磨练 临床试验开发和职业/研究成功的基本技能；2)监督个性化患者- 针对每个学者的兴趣和需要定制的研究项目；以及3)监督 学者培训，以确保完全胜任的跨学科研究人员的逐步发展 能够成功地进行癌症临床试验。这些具体目标将造就一大批训练有素的科学家。 站在创新、有影响力的循证研究的前沿，谁可以监督涵盖 从基础科学(靶标识别和药物发现)到翻译的整个研究连续体 科学(药物开发和相关科学)到临床研究。通过这样做，我们提供了潜在的 提高临床科学家的成功，改善癌症患者的预后。

PROJECT SUMMARY The overarching goal of the UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program (CDP) is to nurture clinician or basic/translational junior faculty to become independent, patient- oriented cancer researchers who are highly trained in translational, team-driven research. Using 1) core competencies, 2) advanced oncology coursework, 3) career development, 4) mentored research, and 5) cross- discipline exposure, the CDP provides two new scholars per year (six at any one time) a three-year career development program aimed at honing ideas and skills that go far beyond their initial disciplinary boundaries. Scholars will overcome language and cultural barriers that typically exist between clinical and basic/translational researchers, take advantage of the collaborative research environment at UC Davis, participate in multidisciplinary and translational forums, and gather essential skills in research design, clinical trial development, team science, grant writing, ethical conduct of research, communication, and career development. The vision is to enhance translational research by training physician-scientists to incorporate and utilize basic/correlative science in their pursuit of clinical trials ("Clinical Track"), and conversely, driving basic scientists towards patient-driven drug development and clinical research ("Basic/Translational Track"). To maintain the emphasis on patient-driven clinical research, CDP scholars, under the mentorship of both a clinical mentor and basic/translational mentor, will be required to develop and initiate/conduct their own investigator-initiated clinical trial during the training period. The program will leverage the outstanding research, training, and evaluation expertise and infrastructure of the NCI-designated UC Davis Comprehensive Cancer Center, NCATS-funded Clinical and Translational Research Center (CTSC), and School of Medicine Career Development Program. It will be overseen and enhanced by a highly organized internal Oversight Committee and external Advisory Board. Overall, the CDP seeks to accomplish the following specific aims: 1) Offer a competency-based didactic curriculum to promote team science, encourage translational research, and hone essential skills for clinical trial development and career/research success; 2) Oversee individualized patient- oriented research projects customized to the interests and needs of each scholar; and 3) Provide oversight of scholar training to ensure the progressive development of fully competent interdisciplinary researchers who can successfully conduct cancer clinical trials. These specific aims will build a critical mass of trained scientists at the forefront of innovative, impactful, evidence-based research, who can oversee projects encompassing the entire continuum of research from basic science (target identification and drug discovery) through translational science (drug development and correlative science) to clinical investigation. By doing so, we offer the potential of enhancing the success of clinician scientists and improving outcomes for cancer patients.